11,000 Shares in Marina Biotech, Inc. (MRNA) Purchased by Bainco International Investors

Bainco International Investors acquired a new stake in Marina Biotech, Inc. (OTCMKTS:MRNA) in the first quarter, Holdings Channel reports. The firm acquired 11,000 shares of the biotechnology company’s stock, valued at approximately $224,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRNA. Canada Pension Plan Investment Board purchased a new stake in shares of Marina Biotech during the fourth quarter worth approximately $24,430,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Marina Biotech during the first quarter worth approximately $1,051,000. Parallel Advisors LLC purchased a new stake in shares of Marina Biotech during the first quarter worth approximately $207,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Marina Biotech during the fourth quarter worth approximately $146,000.

Several equities research analysts have recently commented on MRNA shares. Zacks Investment Research cut Marina Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th. Oppenheimer restated a “buy” rating on shares of Marina Biotech in a research note on Tuesday, March 19th. Chardan Capital started coverage on Marina Biotech in a research note on Friday, April 5th. They set a “buy” rating and a $40.00 price target for the company. Finally, Piper Jaffray Companies upped their price target on Marina Biotech from $24.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Marina Biotech presently has an average rating of “Buy” and an average price target of $27.10.

OTCMKTS:MRNA opened at $23.12 on Thursday. Marina Biotech, Inc. has a 1 year low of $13.03 and a 1 year high of $29.79.

Marina Biotech (OTCMKTS:MRNA) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.01). The business had revenue of $16.03 million during the quarter, compared to analysts’ expectations of $33.59 million.

COPYRIGHT VIOLATION WARNING: This story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2019/05/16/11000-shares-in-marina-biotech-inc-mrna-purchased-by-bainco-international-investors.html.

Marina Biotech Company Profile

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

Read More: Green Investing

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marina Biotech, Inc. (OTCMKTS:MRNA).

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.